Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year High at $1,165.95

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $1,165.95 and last traded at $1,159.10, with a volume of 34372 shares changing hands. The stock had previously closed at $1,156.86.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. TD Cowen raised their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Piper Sandler raised their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, Argus upped their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,097.05.

Regeneron Pharmaceuticals Trading Up 1.5 %

The stock’s fifty day moving average price is $1,063.88 and its 200 day moving average price is $992.29. The stock has a market cap of $129.36 billion, a P/E ratio of 34.18, a PEG ratio of 2.99 and a beta of 0.13. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.79 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares in the company, valued at $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares in the company, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold 40,561 shares of company stock worth $40,585,963 over the last three months. 7.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Mackenzie Financial Corp grew its position in Regeneron Pharmaceuticals by 3.7% in the 2nd quarter. Mackenzie Financial Corp now owns 57,964 shares of the biopharmaceutical company’s stock worth $60,922,000 after purchasing an additional 2,074 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after buying an additional 2,270 shares during the last quarter. MBB Public Markets I LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2,095.9% in the 2nd quarter. MBB Public Markets I LLC now owns 7,532 shares of the biopharmaceutical company’s stock worth $7,916,000 after buying an additional 7,189 shares during the last quarter. DE Burlo Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 7.4% in the second quarter. DE Burlo Group Inc. now owns 8,690 shares of the biopharmaceutical company’s stock worth $9,133,000 after acquiring an additional 600 shares during the period. Finally, Decatur Capital Management Inc. increased its position in Regeneron Pharmaceuticals by 2.6% during the second quarter. Decatur Capital Management Inc. now owns 2,674 shares of the biopharmaceutical company’s stock valued at $2,810,000 after acquiring an additional 69 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.